Business
Recursion Pharmaceuticals and FDA Reach Key Phase 3 Trial Design Agreement for Potential FAP Therapy
Recursion secures FDA alignment on pivotal clinical study of REC-4881, aiming to address a critical gap in treatments for familial adenomatous polyposis as shares jump on…